<ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">The 2QCY25 results for pharmaceutical sector have started to
come in, reflecting a mixed performance, with some companies posting growth
while others underperformed. The sector underwent a major shift last year when
the government deregulated prices of non essential medicines. This policy
change has driven a sharp rise in revenues and margins over the past four
quarters, though the extent and timing of the impact varied across companies
depending on their cost adjustments, seasonality, and product mix.</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">In 2QCY25, HALEON, HPL & ABOT recorded topline growth of
~16%, 15% & 10% QoQ, respectively. The increase is mainly attributable to
better product av...
